12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

H5N1 VLP Vaccine: Interim Phase II data

Interim data from a double-blind, placebo-controlled, Canadian Phase II trial in 135 healthy volunteers ages 18-60 showed that 2 doses of 20, 30 or 45 µg H5N1 VLP Vaccine given 21 days apart were well tolerated with...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >